Cincinnati Children's Hospital Medical Center

University of Cincinnati

Jarek Meller

David A Hildeman

Suhas G Kallapur

Alexander Thorman

Andrew B Herr

David Plas

Maria Franciszka Czyzyk-Krzeska

Julio Alberto Landero Figueroa

Shuchi Gulati

Bhargav Vemuri

John Thomas Cunningham, Iv

The disclosure provides compounds of Formula I and their use in methods of modulating an immune response by inhibiting BFL1, and related methods for treating and preventing diseases and disorders characterized by inflammation, especially neutrophil induced inflammation.

Compounds useful for inhibiting BFL1 and their use in therapy

The disclosure provides methods of modulating an immune response by inhibiting BFL1, and related methods for treating and preventing diseases and disorders characterized by inflammation, especially neutrophil induced inflammation.

Methods of attenuating an immune response by inhibition of BFL1

A method of diagnosing the likelihood of recurrence of clear cell renal cell carcinoma is provided. The method involves a) detecting the gene expression signatures of mitochondrial electron transport chain subunits, mitochondrial ribosomal proteins, major histocompatibility complex class II (MHC-II) proteins or combinations thereof in a kidney tumor tissue sample; and b) determining that the subject has an elevated risk of recurrence of clear cell renal cell carcinoma if the gene expression signatures include certain sequences. In another embodiment, the method uses copper levels to diagnose the likelihood of recurrence of clear cell renal cell carcinoma.

Diagnostic tools and treatments for clear cell renal cell carcinoma

Growing community of inventors

Cincinnati, OH, United States of America

Jarek Meller